Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Relatively mild symptoms after chronic overdose with a double-dose encorafenib: a case report.

Anti-cancer drugs - 1 Jun 2021

Mian Paola, Meussen Elvera, Piersma Djura, Lankheet Nienke A G

Abstract excerpt

Encorafenib (Braftovi) is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation, in combination with binimetinib (Mektovi). According to the product label of encorafenib, there are no specific treatment recommendations in case of an overdose. We report on a 63-year-old man who ingested a double dose (900 mg) of encorafenib for 16 days. He developed...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Benzimidazoles
Share to Carbamates
Share to Communicable Disease Control

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Monitoring

Share to Liver Function Tests

Share to Long QT Syndrome

Share to Sulfonamides

Share to Vomiting

Source

Identifiers

PMID: 33587356
DOI: 10.1097/CAD.0000000000001052

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Relatively mild symptoms after chronic overdose with a double-dose encorafenib: a case report.PMID 33587356Read ↗

An evaluation of encorafenib for the treatment of melanoma.Semantic proximity Read ↗

A Real-World Disproportionality Analysis of Two Typical First-Generation TRK Inhibitors: Findings from the FDA Adverse Event Reporting System DatabaseSemantic proximity Read ↗

Management of Pyrexia Associated with the Combination of Dabrafenib and Trametinib: Canadian Consensus Statements.Semantic proximity Read ↗

The Impact of Excessive Paracetamol Use on the Human Body: A Comprehensive ReviewSemantic proximity Read ↗

Common Causes and Characteristics of Adverse Drug Reactions in Older Adults: A Retrospective StudySemantic proximity Read ↗

Real-World Data Analysis of Vascular and Lymphatic Adverse Events Associated with Anti-Tumor Angiogenesis Drugs: A WHO-VigiAccess StudySemantic proximity Read ↗

Adverse Events Associated with Encorafenib Plus Cetuximab in Patients with BRAFV600E-mutant Metastatic Colorectal Cancer: An in-depth Analysis of the BEACON CRC Study.Semantic proximity Read ↗

Rhabdomyolysis Caused by Gefitinib Overdose.Semantic proximity Read ↗

Distinct Adverse Event Profiles of Eight Chemotherapeutic Agents: A FAERS Database Analysis Focusing on Peripheral NeuropathySemantic proximity Read ↗

Management of adverse events from the treatment of encorafenib plus cetuximab for patients with BRAF V600E-mutant metastatic colorectal cancer: insights from the BEACON CRC study.Semantic proximity Read ↗

Medicinal Cannabis - Potential Drug InteractionsSemantic proximity Read ↗

Acute renal failure under encorafenib, binimetinib and cetuximab for BRAF V600E-mutated colorectal cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.